Mankind Pharma IPO: The subscription period will begin on April 25 and end on April 27, and Mankind Pharma, India’s second-largest pharmaceutical firm in terms of sales volume for the fiscal year 2022, will be open for subscription. On April 24, the anchor bidding will begin.
The first public offering comprises the promoters and existing shareholders making a pure offer to sell up to 40.06 million shares. Ramesh Juneja may own up to 3.71 million shares, Rajeev Juneja may own up to 3.51 million shares, Sheetal Arora may own up to 2.80 million shares, Cairnhill CIPEF Ltd may own up to 17.41 million shares, Cairnhill CGPE Ltd may own up to 2.62 million shares, Beige Ltd may own up to 9.96 million shares, and Link Investment Trust may own up to 50,000 shares. The business will have the second-largest sales volume for the Financial Year 2022 and will rank as the fourth-largest pharmaceutical firm in India in terms of domestic sales. It creates, produces, and sells a wide variety of pharmaceutical formulations for both acute and chronic conditions, as well as a number of consumer healthcare items.
Mankind Pharma IPO Dates
The subscription period will begin on April 25 and end on April 27, and Mankind Pharma, India’s second-largest pharmaceutical firm in terms of sales volume for the fiscal year 2022, will be open for subscription. On April 24, the anchor bidding will begin.
Chrys Capital and Capital International, two private equity firms, provide funding to Mankind Pharma, which produces the well-known condom brand Manforce Condoms, the pregnancy test kit Prega News, and the emergency contraceptive brand Unwanted-72. The business was started by Ramesh Juneja, and in 1995 it turned into a pharmaceutical company with complete integration. It creates, produces, and sells a wide variety of pharmaceutical formulations for use in acute and chronic therapeutic areas as well as a number of consumer healthcare items.
Mankind Pharma IPO Details
| IPO Date | Apr 25 to Apr 27, 2023 |
| Face Value | ₹1 per share |
| Price | To be announced |
| Lot Size | To be announced |
| Total Issue Size | 40,058,844 shares (aggregating up to ₹To be announced Cr) |
| Offer for Sale | 40,058,844 shares of ₹1 (aggregating up to ₹To be announced Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
Important Dates of Mankind Pharma IPO
Quicktouch Technologies IPO opens on Apr 18, 2023, and closes on Apr 21, 2023.
| Event | Tentative Date |
|---|---|
| Opening Date | Apr 25, 2023 |
| Closing Date | Apr 27, 2023 |
| Basis of Allotment | Apr 28, 2023 |
| Initiation of Refunds | May 2, 2023 |
| Credit of Shares to Demat | May 3, 2023 |
| Listing Date | May 4, 2023 |
Mankind Pharma IPO Lot Size
The Quicktouch Technologies IPO lot size is To be announced in shares.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 2000 | To be announced |
| Retail (Max) | 1 | 2000 | To be announced |
| HNI (Min) | 2 | 4,000 | To be announced |
Objects of the Mankind Pharma IPO
All of the offer proceeds will be received by the selling shareholders in proportion to the offered shares that each selling shareholder sold as part of the offer; the company will not receive any of the offer proceeds.
About Mankind Pharma IPO
Mankind Pharma Limited was founded in 1991 and develops, produces, and sells pharmaceutical formulations for a range of acute and chronic therapeutic areas as well as a number of consumer healthcare items.
The company operates in India in a number of acute and chronic therapeutic areas, including respiratory, neuro/CNS, cardiovascular, gastrointestinal, anti-diabetic, and anti-infectives.
It has over 36 brands, including Manforce (Rx), Moxikind-CV, Amlokind-AT, Unwanted-Kit, Candiforce, Gudcef, Glimestar-M, Prega News, Dydroboon, Codistar, Nurokind-Gold, Nurokind Plus-RF, Nurokind-LC, Asthakind-DX, Cefakind, Monticope, Telmikind-H, Telmikind, Gudcef-CV, and Unwanted-72, among them.
One of the biggest medical representative distribution networks in the Indian pharmaceutical market (“IPM”) belongs to Mankind Pharma. During the Financial Year 2022, their formulations were prescribed by more than 80% of Indian doctors, and they were rated fourth in terms of domestic sales.
The business received The Best of Bharat Awards 2022 from exchange4media in the year 2022, a Silver Medal from the National Awards for Manufacturing Competitiveness Assessment 2021 established by International Research Institute for Manufacturing, a Silver Award for a Good Health Brand at the IHW Awards 2021 in the year 2021, the Best Condom Brand of the Year Award at the Sex Brand Awards, Pharma OTC Company of the Year Award at the Pharma Excellence Awards 2018, and the Award for Best Design in H.